EcoDrugPlus

B-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSSPAG00000008939
Gene Symbol: BRAF
3 Cross references
218 Possible Orthologues:

Bcl2 Apoptosis Regulator

Ensembl ID : ENSSPAG00000022884
Gene Symbol: BCL2
3 Cross references
176 Possible Orthologues:

Bcl2 Like 1

Ensembl ID : ENSSPAG00000001484
Gene Symbol: BCL2L1
3 Cross references
226 Possible Orthologues:

Bcl2 Like 1

Ensembl ID : ENSSPAG00000021255
Gene Symbol: BCL2L1
3 Cross references
216 Possible Orthologues:

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSSPAG00000007710
Gene Symbol: BCR
3 Cross references
196 Possible Orthologues:

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSSPAG00000006102
Gene Symbol: BCR
3 Cross references
205 Possible Orthologues:

Bdnf/nt-3 Growth Factors Receptor-Like

Ensembl ID : ENSSPAG00000011650
Gene Symbol: LOC103364540
3 Cross references
207 Possible Orthologues:

Bruton Tyrosine Kinase

Ensembl ID : ENSSPAG00000001288
Gene Symbol: BTK
3 Cross references
203 Possible Orthologues:

Bruton Tyrosine Kinase

Ensembl ID : ENSSPAG00000010436
Gene Symbol: BTK
3 Cross references
203 Possible Orthologues:

C-C Chemokine Receptor Type 9-Like

Ensembl ID : ENSSPAG00000020229
Gene Symbol: LOC103372159
3 Cross references
188 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSSPAG00000008920
Gene Symbol: CCR9
3 Cross references
193 Possible Orthologues:

C-X-C Motif Chemokine Receptor 2

Ensembl ID : ENSSPAG00000009695
Gene Symbol: CXCR2
3 Cross references
275 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).